LenioBio strengthens its Board of Directors along with closing €11.5m Series A funding

– GERMANY, Dusseldorf –  LenioBio GmbH, a German life sciences biotech offering a disruptive protein manufacturing technology, ALiCE, closed its Series-A Extension round with a total investment volume of €11.5 million. The investment round, which was closed in November 2021, is led by LenioBio’s current investor Bridford Group, a PE investor focusing on founder-led businesses with long-term growth potential and concerned with societal or environmental welfare.

The raised funds will be used to accelerate LenioBio’s continuous efforts in research and development of the ALiCE technology, process improvement of large-scale manufacturing, and mapping of the various market opportunities.

Along with the investment round, LenioBio strengthens its Board of Directors with additional Non-Executive directors including Thomas Harding, Leopoldo Zambeletti, and Karen Fallen.

“Our new Board members bring extensive experience in different fields of the business. Their input will be crucial in setting the mid and long-term strategy of the company which will now focus on the validation of the ALiCE technology. With the new Board composition, LenioBio is well-positioned to achieve the next stage on our journey.” said Dr. Remberto Martis, CEO of LenioBio.

About Thomas Harding

Thomas Harding is a partner at Bridford Group and a director of several portfolio companies, such as Hudson River Biotechnology and Touchlight Holdings Limited. He previously worked on TMT investments at Access Industries, after joining Weil, Gotshal, and Manges’ private equity department and has been active in several other directors and officer positions.

He has a MA from the University of Cambridge and subsequently studied at City University (law) and London Business School (finance).

About Karen Fallen

Karen Fallen is currently the CEO of Touchlight DNA Services and has extensive experience in the Biopharma industry. Having worked for Lonza for 14 years, she held various leading positions in clinical development and manufacturing as well as in-licensing and business development.

She received her degree in Applied Biology, Industrial Biology, Immunology, and Biotechnology from Thames Valley University.

About Leopoldo Zambeletti

Leopoldo Zambeletti started his career as an auditor at KPMG and has more than 19 years of experience as an investment banker, i.e. leading the European Healthcare Investment Banking team at JP Morgan and Credit Suisse. As an independent strategic consultant to life science companies, he is since 2013 advising companies on financial deals, out-licensing, and M&A.

He graduated with a BA in Business at Bocconi University in Milan, Italy.

About LenioBio

LenioBio is a protein expression platform company committed to the advancement of transformative technology for the discovery, development, and large-scale production of proteins, unconstrained by the limitations of the cell.

LenioBio was established as a legal entity in Germany in September 2016, with offices in Dusseldorf and R&D and production labs in Aachen.

For more information: https://www.leniobio.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.